---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-067030"
form_type: "8-K"
ticker: null
cik: "0001621227"
company_name: "Adaptimmune Therapeutics PLC"
filed_at: "2023-06-01T23:59:59+00:00"
generated_at: "2026-06-14T09:24:39.057891+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Adaptimmune completes all-stock combination with TCR2; creates solid tumor cell therapy leader

## Summary
- Merger closed June 1, 2023; Adaptimmune shareholders own ~75%, former TCR2 stockholders own ~25% of combined company.
- BLA for afami-cel (synovial sarcoma) on track for mid-2023; 70% of responders alive at 2 years in SPEARHEAD-1 trial.
- New directors appointed: Andrew Allen, Priti Hegde, Garry Menzel (ex-TCR2); Barbara Duncan and James Noble resigned.
- Combined pipeline targets MAGE-A4, mesothelin, PRAME, CD70; company funded into early 2026.
- Dr. Garry Menzel receives separation: $1.28M severance (18 months), $343,750 bonus, $171,875 transaction bonus.

## SEC filing metadata
- accession: 0001104659-23-067030
- form_type: 8-K
- cik: 0001621227
- company_name: Adaptimmune Therapeutics PLC
- filed_at: 2023-06-01T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.01, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1621227/000110465923067030/0001104659-23-067030-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1621227/000110465923067030/tm2317177d3_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-067030
- JSON: https://secwatch.observer/filing/0001104659-23-067030.json
- Plain text: https://secwatch.observer/filing/0001104659-23-067030.txt

## Key facts
- Executive change
  Andrew R. Allen was appointed as director at Adaptimmune Therapeutics PLC.
  - Action: appointed
  - Role: director
  source text: the Adaptimmune Board appointed Andrew R. Allen, M.D., Ph.D.; Priti Hegde, Ph.D.; and Garry E. Menzel, Ph.D., each of whom were members of the board of directors of TCR 2 , to serve as directors for a term commencing upon the Effective Time.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1621227/000110465923067030/0001104659-23-067030-index.htm
- Executive change
  James Noble resigned as director at Adaptimmune Therapeutics PLC.
  - Action: resigned
  - Role: director
  source text: Barbara Duncan and James Noble resigned as directors of Adaptimmune.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1621227/000110465923067030/0001104659-23-067030-index.htm
- Executive change
  Barbara Duncan resigned as director at Adaptimmune Therapeutics PLC.
  - Action: resigned
  - Role: director
  source text: Barbara Duncan and James Noble resigned as directors of Adaptimmune.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1621227/000110465923067030/0001104659-23-067030-index.htm
- Executive change
  Garry E. Menzel was appointed as director at Adaptimmune Therapeutics PLC.
  - Action: appointed
  - Role: director
  source text: the Adaptimmune Board appointed Andrew R. Allen, M.D., Ph.D.; Priti Hegde, Ph.D.; and Garry E. Menzel, Ph.D., each of whom were members of the board of directors of TCR 2 , to serve as directors for a term commencing upon the Effective Time.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1621227/000110465923067030/0001104659-23-067030-index.htm
- Executive change
  Priti Hegde was appointed as director at Adaptimmune Therapeutics PLC.
  - Action: appointed
  - Role: director
  source text: the Adaptimmune Board appointed Andrew R. Allen, M.D., Ph.D.; Priti Hegde, Ph.D.; and Garry E. Menzel, Ph.D., each of whom were members of the board of directors of TCR 2 , to serve as directors for a term commencing upon the Effective Time.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1621227/000110465923067030/0001104659-23-067030-index.htm
- M&A Transactions
  Adaptimmune Therapeutics PLC completed an acquisition involving TCR 2 Therapeutics Inc. for all-stock transaction (closed 2023-06-01).
  - Action: acquisition
  - Counterparty: TCR 2 Therapeutics Inc.
  - Consideration: all-stock transaction
  - Closing: 2023-06-01
  source text: On June 1, 2023, Adaptimmune Therapeutics plc, a public limited company incorporated in England and Wales (“ Adaptimmune ”), completed the previously announced strategic combination contemplated by that certain Agreement and Plan of Merger, dated as of March 5, 2023, as amended by Amendment No. 1 to the Agreement and Plan of Merger entered into as of April 5, 2023 (as amended, the " Merger Agreement "), with TCR 2 Therapeutics Inc., a Delaware corporation (" TCR 2 "), Adaptimmune, and CM Merger Sub, Inc., a Delaware corporation and an indirect wholly-owned subsidiary of Adaptimmune (" Merger Sub ").
  evidence_url: https://www.sec.gov/Archives/edgar/data/1621227/000110465923067030/0001104659-23-067030-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.